Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Cerevel Therapeutics Hldg Inc (NQ: CERE )

13.66 UNCHANGED
Streaming Delayed Price Updated: 9:50 AM EST, Jan 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,559
Open 13.94
Bid (Size) 13.58 (6)
Ask (Size) 13.85 (1)
Prev. Close 13.66
Today's Range 13.58 - 13.94
52wk Range 9.000 - 18.84
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Cerevel Therapeutics Announces the Appointments of Deval Patrick and Deborah Baron to its Board of Directors
From GlobeNewswire News Releases
Cerevel Therapeutics to Host Inaugural Virtual R&D Event
From GlobeNewswire News Releases

Performance

YTD
-16.76%
-16.76%
1 Month
-21.54%
-21.54%
3 Month
+38.26%
+38.26%
6 Month
+38.26%
+38.26%
1 Year
+38.26%
+38.26%

More News

Read More
Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors
From GlobeNewswire News Releases
Cerevel Therapeutics to Host Investor Webcast Moderated by Stifel
From GlobeNewswire News Releases
Cerevel Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
From GlobeNewswire News Releases
Cerevel Therapeutics Announces Third Quarter 2020 Financial Results and Key Business Highlights
From GlobeNewswire News Releases
Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences
From GlobeNewswire News Releases
7 hard lessons for investors from the DoorDash and Airbnb IPOs
Tags SPX SPOT ASAN
From MarketWatch
Last Week's Notable Insider Buys: Kraft, IBM, Vertex And More
Tags New Relic Impinj Insider Trades
From Benzinga
Last Week's Notable Insider Buys: Kraft, IBM, Vertex, And More
Tags Stocks / Equities
From Blogs - TalkMarkets
The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes
Tags SRPT ICPT ORPH
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.